I would say the cost to capture patients in the UK may be higher than Australia.
If Althea try to scale their business, they would be scaling their losses.
I guess this is what you get when you get a group of people with minimal pharma experience running a pharmaceutical business.
AGH's stock price is pretty much the lowest price it has ever been in the last 15 months for a reason. IMHO, I see the best solution is sacking the existing management and bringing in experienced pharma execs to replace the existing crew.
I would say the cost to capture patients in the UK may be higher...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.56M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.5¢ | $10.27K | 410.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000000 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 178306 | 2 |
View Market Depth
| Last trade - 13.07pm 02/07/2025 (20 minute delay) ? |
| AGH (ASX) Chart |